AllDocs -> cancers

Spring 2005 Issue 1 Gastrointestinal Cancer Rapid Medical Donation Program Newsletter Inside: Meet The Lab 2 Participant Family Corner 3 Contact Information 4 Related Programs - NFPTR 6 Related Programs - Breast Cancer Medical Donation 6 The Johns Hopkins University School of MedicineKnowledge, For The World I write to you today with two goals-to introduce both myself and my laboratory to you, and to provide an update of the tremendous impact your loved one has made by participating in the Johns Hopkins Gastrointestinal Cancer Rapid Medical Donation Program (GICRMDP). Who am I? Born and raised in Bayshore, New York, I learned at the early age of 10 how devastating a cancer diagnosis can be when my father passed away of advanced colorectal cancer . When he was diagnosed, the ...

1 7 th WORLD CONGRESS ON GASTROINTESTINAL CANCER 15-18 June, 2005, Barcelona (some selected aspects discussed on the pancreas) This annual meeting was once again held in Barcelona, and after the change of meeting place to CCIB convention center near the Forum 2004, the frame of the meeting was even better than before. For those who had the possibility to stay a day before or after the congress, Barcelona is one of the most interesting European towns today – a long history of culture, the most thrilling architecture in the world, and vibrant music, art, football and good food today. There is something for everybody, and always more to see and experience than what is possible to find time for. Moreover, the tourist attractions are well organised, and the Spaniards really try to get the tourists to feel at ease. The congress i growing for each year – both concerning number of ...

DRAFT PATIENT MANAGEMENT FRAMEWORK FOR CONSULTATION Patient Management Frameworks Introduction The purpose of this consultation document is to ask for your feedback on the draft Patient Management Framework for the Upper Gastrointestinal ( Pancreatic) tumour stream. The draft Framework is the culmination of a series of workshops with clinicians and consumers and will continue to be modified following consultation and feedback from Integrated Cancer Services, clinicians, consumers and peak professional and consumer bodies. The Frameworks are based predominantly on current best practice including clinical guidelines, care pathways, consensus statements, standards and research that exist to support optimal care at the critical points. However, in many cases they are a statement of consensus regarding currently accepted approaches to treatment. Background A Cancer Services Framework ...

1 Newer Approaches to the Prevention of Gastrointestinal Cancer Martin Lipkin Strang Cancer Research Laboratory at The Rockefeller University, Strang Cancer Prevention Center and The New York Hospital-Corneu Medical Center New York, NY 10021 USA To identify the efficacy of chemopreventive agents and their effect on progressive stages of colonic preneoplasia and tumor evolution, new preclinical models have recently been developed. Some of these models have targeted mutations that modify the incidence and progression of neoplastic lesions. In one model of inherited predisposition to colon cancer mice carrying a truncated Apc allele with a nonsense mutation in exon 15 (Apc1638 mice) develop multiple gastrointestinal lesions, including adenomas and carcinomas, focal areas of high-grade dysplasia (fad) and polypoid hyperplasias with fads. The incidence of inherited intestinal neoplasms ...

TNFerade TM Combined with Chemoradiation in Gastrointestinal Cancer: Phase I/II Studies in Unresectable Locally Advanced Pancreatic and Resectable Esophageal Cancer Neil Senzer, MD Scientific Director Mary Crowley Medical Research Center US Oncology, Dallas, TX On behalf of the TNFerade TM Investigators Page 2 What is TNFerade TM ? • TNFerade is a second-generation (E1-, partial E3-, and E4-deleted) adenovector carrying the transgene encoding for TNF- a • A radiation-inducible promoter (Egr-1) is incorporated in the construct to optimize spatial and temporal gene expression following ionizing radiation Page 3 Rationale of TNFerade and Radiation Therapy Transcriptional targeting using a radiation- inducible, radio-sensitizing ...

Orthotopic transplantation model of human gastrointestinal cancer and detection of micrometastases Jun Hui Cui 1 , Uwe Krueger 2 , Doris Henne-Bruns 2 , Bernd Kremer 2 and Holger Kalthoff 2 Subject headings mice, nude; gastrointestinal neoplasms/ pathology; neoplasm seeding; neoplasm metastasis Cui JH, Krueger U, Henne-Bruns D, Kremer B, Kalthoff H. Orthotopic transplantation model of human gastrointestinal cancer and detection of micrometastases. World J Gastroenterol , 2001;7(3):381-386 Abstract AIM To establish a relevant animal model of human gastrointestinal cancer, which can be used for repetitive investigations, so as to improve our understanding and management of carcinogenesis and cancer metastasis. METHODS Intact tissues of human colorectal and pancreatic cancers ...

Received: 10 December 1998 Accepted: 25 May 1999 Abstract Background: Principles of the treatment of ga strointestinal ca ncer wi th gene therapy evolved from the advent of techniques in mo- lecular biology, from increasing in- sights into the molecular basis of tu- morigenesis and from the need to de- velop more efficient treatment mo- dalities. Any gene therapy approach has to take two major tasks into con- sideration: the therapeutic gene has to be delivered into the target cell population with high efficiency, specificity and safety, and has to act in a way that provides a benefit to the patient. Discussion: Data on 22 clinical trials on malignancies of the ga strointestinal tr act are available. They utilize a variety of gene-deliv- ery methods and target cell popula- tions, and there is considerable vari- ety among their strategies. Gene transfer ...

1 WORLD CONGRESS ON GASTROINTESTINAL CANCER Barcelona, 16-19 June, 2004 The world congresses of gastrointestinal cancer has emerged from the regular meetings on pharmacological treatments of colorectal cancer, partly based on Eric Van Cutsem’s (Brussels) personal interest of this disease and definition of an international forum for discussing the development and future strategies. The world congress is now also concerned with the malignancies of liver, bile-ducts, pancreas and all of the oesofagus-stomach-bowel and attracts more than 2000 people; mostly from Europe, but there were also delegates from all other parts of the world. Distinct from most other annual congresses there is no famous world association or federation behind the meeting, but rather a smaller group of dedicated oncologists backed by the pharmaceutical industry with oncology interest. The conference still has no double sessions ...

Novartis International AG Novartis Communications CH-4002 Basel Switzerland Tel + 41 61 324 2200 Fax + 41 61 324 3300 Internet address: http://www.novartis.com *In the US: Gleevec ® (imatinib mesylate) 1/2 MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG Glivec ® approved in Japan for treatment of life-threatening gastrointestinal cancer Basel, Switzerland, 17 July 2003 – Novartis announced today that health authorities in Japan have approved Glivec ® (imatinib)* for the treatment of patients with KIT (CD117) positive gastrointestinal stromal tumors (GISTs), a life-threatening cancer. Historically, GISTs have been very difficult to treat due to their resistance to treatment with available chemotherapy and radiation therapy. Previously, surgery ...

PRACTICAL GASTROENTEROLOGY • MARCH 2004 52 INTRODUCTION N umerous studies have been done to examine what role diet plays in protection against gastrointesti- nal cancers. In order to make the best suggestions for physicians and patients, a careful review of the data is provided. The area of diet and cancer prevention is evolving, and, at the current time, much of the data is epidemiological or from basic science animal models. Some of the data is from humans in retrospective for- mat, prospective cohorts, and a few randomized placebo controlled studies. In order to understand the evolution and how suggestions are being formed, it is essential to review all of the studies available as each type has value. This article provides a review of the best data available and makes suggestions based on the literature at hand in regards to nutrients, diet, and cancer ...

Long-acting Repeatable (Lar) Octreotide for Clinical Management of Gastrointestinal Cancer a report by Alessandra Mosca Managing Director, Department of Clinical Oncology, San Luigi Hospital, Orbassano, Italy on behalf of Novartis Pharma AG e-mail: ale.mos@libero.it Page 2 O C T R E O T I D E L A R I N G A S T R O I N T E S T I N A L T U M O U R S 2 Abstract Octreotide represents a novel approach to the treatment of various endocrinological and oncological disorders. Its effects are mediated through its interaction with the somatostatin receptor subtype 2, and to a lesser extent subtypes 5 and 3, and subsequent effects on hormone secretion. A long-acting repeatable (LAR) formulation of octreotide is now available. It is administered by intramuscular injection every 4 weeks. Results to date suggest that octreotide LAR appears ...

Page 1 GASTROINTESTINAL CANCER ANTIGEN (CA-199) ENZYME IMMUNOASSAY TEST KIT Catalog Number: GBE-1006 Intended Use Enzyme Immunoassay for the Quantitative Measurement of Gastrointestinal Cancer Antigen (CA -199) EIA in Human Serum Introduction A group of Sialosyl Lewis Antigen (SLA) defined as a mucin type of glycoprotein such as CA 19-9, CA 195, has come to be recognized as circulating cancer associated antigen for gastrointestinal cancer ( GI tumor antigen). Malignancies of pancreas, stomach and colon express these markers in a significant number of such patients. The GI Tumor Antigen ELISA test will measure CA 19-9 like GI tumor antigen in sera. It provides an aid in the evaluation of symptomatic patients suspected of having pancreatic cancer or related diseases, and as an aid in monitoring pancreatic cancer. Together with ...

Anaheim, CA 92807 1-800-222-9880 1268 N. Lakeview Ave. TECO DIAGNOSTICS CA 19-9 ( MICROTITER ASSAY ) Enzyme Immunoassay for the Quantitative Determination of Gastrointestinal Cancer Antigen CA 19-9 in Human Serum F OR I N V ITRO D IAGNOSTIC U SE O NLY Store at 2 to 8 ° C. P ROPRIETARY AND C OMMON N AMES CA19-9 Enzyme Immunoassay I NTENDED U SE For the quantitative determination of the Cancer Antigen CA19-9 concentration in human serum. I NTRODUCTION A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA), such as CA19-9 and CA19-5, have come to be recognized as circulating ...

cancer 1581 Wharton Department of Statistics Data Mining Bob Stine Department of Statistics www-stat.wharton.upenn.edu/~bob Wharton Department of Statistics 2 Overview Applications Marketing: Direct mail advertising (Zahavi example) Biomedical: finding predictive risk factors Financial: predicting returns and bankruptcy Role of management Setting goals Coordinating players Critical stages of modeling process Picking the model <-- My research interest Validation Wharton Department of Statistics 3 Predicting Health Risk Who is at risk for a disease? Costs False positive: treat a healthy person False negative: miss a person with the disease Example: detect osteoporosis without need for x-ray What sort of predictors, ...

To Prevent and Cure Cancer T he Gastrointestinal Cancer (GI) Team at the Arizona Cancer Center focuses on three primary types of cancer —colon, pancreatic and esophageal. Together, these cancers are responsible for approximately 133,600 new cancer cases every year in the United States. Colon cancer alone is the third leading cause of cancer death in the United States. Pancreatic and esophageal cancers both have dismal survival rates of less than four percent. With the joint efforts of physicians and basic scientists, the GI Cancer Team at the Arizona Cancer Center is striving to reduce the incidence and mortality of colon, pancreatic and esophageal cancers. The team believes in a two-pronged approach of basic science research to understand cancer biology, and clinical trials to implement the prevention and treatment strategies ...

ANNUAL RESEARCH REPORT 1998 143 Gastrointestinal Cancer Unit Gastrointestinal Cancer Unit, RMT Sutton (in association with the ICR Section of Medicine) HOSPITAL-BASED CLINICAL RESEARCH Head of Unit D Cunningham MD FRCP T he GI Unit is one of the largest clinical units in the Trust seeing between 900 and 1000 new patients a year with gastro- intestinal malignancies. The Unit enters over 70% of patients into prospective clinical trials, many of which are multicentred UK trials coordinated by the MRC or UKCCCR. New drug development, in collaboration with the CRC Centre for Cancer Therapeutics, and metabolic imaging are also major components of the Unit’s work. We have coordinated the RASCAL group which has shown that the presence of mutations in K-ras conveys an increased risk of relapse following potentially ...

EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 33, No. 1, 8-14, March 2001 Detection of circulating tumor cells in patients with gastrointestinal tract cancer using RT-PCR and its clinical implications Yun Hee Noh 1 , Jung Ah Kim 2 , G-Rewo Lim 1 , Young Tae Ro 1 , Ja Hyun Koo 1 , Yong Sung Lee 2 , Dong Soo Han 3 , Hwon Kyum Park 4 and Myung Ju Ahn 3,5 1 Department of Biochemistry, College of Medicine, Konkuk University, Chungju 380-791, Korea 2 Department of Biochemistry, College of Medicine, Hanyang University, Seoul 133-791, Korea 3 Departments of Internal Medicine and 4 General Surgery, College of Medicine, Hanyang University Kuri Hospital, ...

cancer 1581 Wharton Department of Statistics Profiting from Data Mining Bob Stine Department of Statistics The Wharton School, Univ of Pennsylvania April 5, 2002 www-stat.wharton.upenn.edu/~bob Wharton Department of Statistics 2 Overview Critical stages of data mining process Choosing the right data, people, and problems Modeling Validation Automated modeling Feature creation and selection Exploiting expert knowledge, “insights” Applications Little detail – Biomedical: finding predictive risk factors More detail – Financial: predicting returns on the market Lots of detail – Credit: anticipating the onset of bankruptcy Wharton Department of Statistics 3 Predicting Health Risk Who is at risk for a disease? Example: detect ...

Urology Urological Emergencies in Clinical Practice Hashim, Hashim, Reynard, John, Cowan, Nigel C. 2004, Approx. 185 p. 61 illus., 5 in color., Softcover ISBN: 1-85233-811-3 Männersprechstunde - das Praxishandbuch zu Beratung, Prävention und Therapie Böhm, Michael; Jockenhövel, Friedrich; Weidner, Wolfgang (Eds.) 2004, 418 p. 100 illus. 15 in color, Hardcover ISBN: 3-540-00915-9 English translation Medical Consultation for Men - The Handbook for Advice, Prevention and Therapy Men are the focus in this book - Männersprechstunde has been written for all doctors involved in health care of men. Whether urologist, internist or general practitioner - substantiated information on prevention and therapy of diseases affecting the elderly man plus practical tips from experienced clinicians help the reader advise and treat ...

FRIDAY Joint Symposium: MOGA / ANTIGER Neuroendocrine Tumours – Recent Advances in DIAGNOSIS AND Management 18 Neuroendocrine GEP-tumors: Advances in Diagnosis and Treatment By Kjell Öberg, M.D., Ph.D. Professor Endocrine Oncology Dept. of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden Neuroendocrine tumors of the gastrointestinal tract and pancreas constitute about 2 % of all malignant tumors. They include a number of different tumors, derived from cells of the diffuse neuroendocrine cell-system. The largest group of neuroendocrine tumors are the so called carcinoids with an incidence of about 2.5/100 000 per year. The old classification of neuroendocrine GEP-tumors is based on the embryonic origin, but there is a new WHO- classification taking into the consideration the tumor biology of different subtypes of neuroendocrine tumors. The tumors exhibit substantial differences ...

Royal College of Physicians of Edinburgh UPPER GASTROINTESTINAL CANCER Tuesday 26 October 2004 venue: The Queen Mother Conference Centre Royal College of Physicians of Edinburgh 9 Queen Street Edinburgh EH2 1JQ CPD APPROVED PGEA APPROVED Royal College of Physicians of Edinburgh Upper Gastrointestinal Cancer Tuesday 26 October 2004 Cancers of the oesophagus and stomach are highly lethal and remain a major health problem worldwide. In recent years our understanding of gastric cancer development has greatly improved but there have also been worrying developments with rapid increases in the incidence of adenocarcinomas of the oesophagus and oesophagogastric junction. Reasons for this are not clear but recent research has highlighted some of the pathophysiological and molecular events underlying cancer at these sites. New endoscopic and imaging ...

Abstract. WNT2 gene on human chromosome 7q31 is a paralog of the WNT2B gene on human chromosome 1p13. Rat Wnt2 gene was identified within rat genome draft sequence AC095247.4. Human WNT2 showed 96.4% total-amino-acid identity with rat Wnt2, 96.1% with mouse Wnt2, 68.6% with zebrafish wnt2, and 67.8% with fugu wnt2. WNT2 is an evolutionarily conserved secreted-type glycoprotein belonging to the WNT family. WNT2 mRNA is expressed in human fetal lung and placenta, but almost undetectable in normal gastro- intestinal tract. WNT2 mRNA is frequently up-regulated in human gastric cancer due to tumor-stromal interaction, and WNT2 gene is rarely amplified in human gastric cancer. WNT2 mRNA is also frequently up-regulated in colorectal polyps, primary colorectal cancer of stage A-C, and also in liver metastasis from colorectal cancer. Putative biding sites for estrogen receptor, GATA-1, ...

Abstract: Significant benefits have been gained with pre or peri-operative nutritional support in surgical patients with malnutrition. Recent studies have also shown that some enteral formulas including certain nutrients like glutamine could provide more benefit than the standard formulas. In this prospective-randomized study, the effects of perioperative oral supplement with enteral formulas containing glutamine in comparison with a standard enteral formula in patients who were operated on for GI malignancies were examined. Thirty-two patients were divided into two groups: the study group was given oral supplement with an elemental diet (Alitraq ® ) for 7 days preoperatively and 10 days postoperatively as 30-35% of total daily requirement (standard hospital diet: 65- 70%), while the control group received a polymeric formula (Ensure ® ) as the ...

430 Volume 37, April 2002 Depression: Postpartum Martha P. Fankhauser, MS Pharm Clinical Associate Professor, Department of Pharmacy Practice and Science, The University of Arizona College of Pharmacy, Tucson, AZ 85721 Ahokas A, Kaukoranta J, Wahlbeck K, et al. Estrogen deficiency in severe postpartum depression: Successful treatment with sublingual physiologic 17 beta-estradiol: A preliminary study. J Clin Psychiatry. 2001;62(5):332–6. Altshuler LL, Hendrick V, Cohen LS. Course of mood and anxiety disor- ders during pregnancy and the post- partum period. J Clin Psychiatry. 1998;59(suppl 2):29– 33. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed, text revision. Washington DC: American Psychiatric Press; 2000. Beck CT, Gable RK. Further validation ...